{
    "clinical_study": {
        "@rank": "13128", 
        "arm_group": [
            {
                "arm_group_label": "Oral morphine sulfate", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine"
            }, 
            {
                "arm_group_label": "Buprenorphine", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Buprenorphine 15.9 \u00b5g/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost\n      effective treatment alternative to morphine sulfate in the treatment of Neonatal Abstinence\n      Syndrome (NAS)."
        }, 
        "brief_title": "Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neonatal Abstinence Syndrome", 
            "Neonatal Withdrawal Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neonatal Abstinence Syndrome", 
                "Substance Withdrawal Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Neonatal abstinence syndrome is a condition that affects newborns who are exposed to chronic\n      opioid drugs while they are in a mother's uterus (womb) prior to birth. The current standard\n      of care treatment includes morphine sulfate. Buprenorphine is a drug used in adults to treat\n      narcotic dependence and withdrawal, but has not yet been approved for use in newborns as a\n      treatment alternative for Neonatal Abstinence Syndrome. This investigation is designed to\n      measure if sublingual (under the tongue) buprenorphine is able to reduce hospital length of\n      stay and decrease number of days of drug treatment currently required in treatment of NAS.\n      Another goal will be to understand buprenorphine as a cost effective treatment for NAS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infants of corrected gestational age \u226537 weeks\n\n          -  Chronic opioid exposure in utero\n\n          -  Signs and symptoms of NAS requiring treatment\n\n          -  2 consecutive Finnegan scores \u22658 or any single score \u226512\n\n        Exclusion Criteria:\n\n          -  Concomitant maternal benzodiazepine or alcohol use 30 days prior to enrollment\n\n          -  Life-threatening congenital malformations\n\n          -  Intrauterine growth retardation\n\n          -  Seizure activity or congenital neurologic abnormalities\n\n          -  Concomitant neonatal use of Cytochrome P450 inhibitor or inducers prior to treatment\n\n          -  Inability of mother's consent due to altered mental status or comorbid psychiatric\n             disorder\n\n          -  Neonatal administration of morphine prior to enrollment into study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "1 Year", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708707", 
            "org_study_id": "Banner IRB 01-13-0030"
        }, 
        "intervention": [
            {
                "arm_group_label": "Buprenorphine", 
                "description": "The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.\nInfants initial dose: 15.9 \u00b5g/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 \u00b5g/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days.", 
                "intervention_name": "Buprenorphine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sublingual buprenorphine", 
                    "Other Name: Buprenex (buprenorphine)", 
                    "NDC Number: 12496-0757-1", 
                    "Product Code: 12496-0757"
                ]
            }, 
            {
                "arm_group_label": "Oral morphine sulfate", 
                "description": "Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.", 
                "intervention_name": "Morphine Sulfate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Oral Morphine Sulfate", 
                    "Morphine", 
                    "NDC: 0406-8003-24"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85006"
                }, 
                "name": "Banner Good Samaritan Medical Center NICU"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)", 
        "overall_official": {
            "affiliation": "Banner Good Samaritan Medical Center", 
            "last_name": "Gregory Martin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of days of hospital admission", 
            "measure": "Hospital length of stay", 
            "safety_issue": "No", 
            "time_frame": "Up to hospital discharge, an anticipated average of 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708707"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of adverse or serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to hospital discharge, with length of stay  currently averaging approximately 4 weeks"
            }, 
            {
                "description": "Cost of buprenorphine as a product of number of days of administration", 
                "measure": "Cost efficiency of buprenorphine", 
                "safety_issue": "No", 
                "time_frame": "At least 48 prior to hospital discharge, with anticipated discharge averaging to be 4 weeks"
            }, 
            {
                "description": "Finnegan methodology to score withdrawal symptoms every four hours of medication administration", 
                "measure": "Withdrawal symptoms", 
                "safety_issue": "No", 
                "time_frame": "Up to hospital discharge, usually occuring on average 4 weeks"
            }, 
            {
                "description": "Number of rescue doses of additional medication", 
                "measure": "Rescue dosage administration", 
                "safety_issue": "No", 
                "time_frame": "Up to hospital discharge, anticipating an average of 4 weeks"
            }
        ], 
        "source": "Pediatrix Medical Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pediatrix Medical Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}